



May 19, 2014

Zosano Pharma, Inc. to Present at the 3rd International Microneedle Conference

Zosano Pharma, Inc. to Present at the 3rd International Microneedle Conference

Fremont, CA — May 19, 2014 — [Zosano Pharma, Inc.](#), a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced that Dr. Peter Daddona, the company's Chief Scientific Officer and Executive Vice President, Research & Development, will present data today on its ZP-Glucagon product candidate at the [3rd International Conference on Microneedles](#), in Baltimore, Maryland.

Dr. Daddona is an invited speaker highlighting next-generation technologies. His presentation, entitled "Drug-Coated Microneedle Patch for Acute Treatments," will focus on the company's ZP-Glucagon product candidate, for the treatment of severe hypoglycemia. ZP-Glucagon uses the company's rapid acting transdermal technology, being developed as an alternative to injections, to deliver Glucagon, a compound that has been proven to increase blood glucose in patients with severe hypoglycemia.

"We are very excited about our ready-to-use, press and apply transdermal system. This has the potential to be a significant advantage for emergency treatment for severe hypoglycemia over currently marketed Glucagon products requiring cumbersome preparation before administration," said Dr. Daddona.

About Zosano Pharma

Zosano Pharma, Inc. is a private biopharmaceutical company and a pioneer in the field of transdermal drug delivery. Zosano is developing products using its proprietary microneedle patch system. Zosano seeks to develop products with significant commercial potential both independently and in collaboration with strategic partners. Zosano's microneedle patch delivers therapeutic compounds through the skin and provides rapid systemic drug delivery in a convenient, needle-free and pain-free system. Zosano's microneedle patch system has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies. Learn more at www.zosanopharma.com.

Media Contact:

Jamie Lacey-Moreira
jamielacey@presscommpr.com
443-212-5260